Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-25T09:10:15.705Z Has data issue: false hasContentIssue false
  • English
  • Français

Some Clinical and Metabolic Aspects of Propranolol in Chronic Schizophrenia

Published online by Cambridge University Press:  29 January 2018

D. J. King ,
S. N. A. Turkson ,
J. Liddle  and
C. D. Kinney
D. J. King
Affiliation:
Department of Therapeutics and Pharmacology, Queen's University of Belfast, and Holywell Hospital, Antrim
S. N. A. Turkson
Affiliation:
Holywell Hospital, Antrim
J. Liddle
Affiliation:
Department of Therapeutics and Pharmacology, Queen's University of Belfast
C. D. Kinney
Affiliation:
Department of Therapeutics and Pharmacology, Queen's University of Belfast
Get access Rights & Permissions [Opens in a new window]

Summary

No benefit attributable to propranolol (1000 mg/day) could be detected in a trial lasting at least 22 weeks, 6 weeks of which was double-blind placebo-controlled, in 5 chronic schizophrenic patients. The mean propranolol CSF/plasma ratio was 0.08, and there was good agreement between CSF and free plasma propranolol levels. Basal plasma prolactin was slightly but insignificantly reduced by propranolol, and metoclopramide-stimulated prolactin release was unaffected. Propranolol was associated with a significant temporary increase in HVA, a non-significant rise in 5-HIAA and a significant decrease in MHPG, in the lumbar cerebrospinal fluid of 4 patients.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 137 , Issue 5 , November 1980 , pp. 458 - 468
Copyright
Copyright © Royal College of Psychiatrists, 1980 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Atsmon, A. I., Blum, M., Steiner, M., Latz, A. & Wijsenbeek, K. (1972) Further studies with propranolol in psychotic patients. Relation to initial psychiatric state, urinary catecholamines and 3-methoxy-4-hydroxyphenylglycol excretion. Psychopharmacologia, 27, 249–54.Google ScholarPubMed
Atsmon, A. I., Blum, M., Wijsenbeek, H., Maoz, B., Steiner, M. & Ziegelman, G. (1971) The short-term effects of adrenergic-blocking agents in a small group of psychotic patients. Psychiatrica Neurologic Neurochirurgia, 74, 251–8.Google Scholar
Belmaker, R. H., Ebstein, R. P., Dasberg, H., Levy, A., Sedvall, G. & van Praag, H. M. (1979) The effect of propranolol treatment in schizophrenia on CSF amine metabolites and prolactin. Psychopharmacology, 63, 293–6.CrossRefGoogle ScholarPubMed
Conway, J., Greenwood, D. T. & Middlemiss, D. N. (1978) Central nervous actions of β-adrenoreceptor antagonists. Clinical Science and Molecular Medicine, 54, 119–24.Google ScholarPubMed
Feighner, J. P., Robins, E., Guze, S. B., Woodruff, R. A., Winokur, G. & Munoz, R. (1972) Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry, 26, 57–63.CrossRefGoogle ScholarPubMed
Gardos, G., Cole, J. O., Volicer, L., Orzack, M. H. & Oliff, A. C. (1973) A dose-response study of propranolol in chronic schizophrenics. Current Therapy and Research, 15, 314–23.Google ScholarPubMed
Garelis, E., Young, S. N., Lal, S. & Sourkes, T. L. (1974) Monoamine metabolites in lumbar CSF: the question of their origin in relation to clinical studies. Brain Research, 79, 1–8.CrossRefGoogle ScholarPubMed
Hanssen, T., Heyden, T., Sundberg, I., Wetterberg, L. & Eneroth, P. (1978) Decrease in serum-prolactin after propranolol in schizophrenia. Lancet, i, 101–2.Google Scholar
Harris, A. D., Letemendia, F. J. J. & Willems, P. J. A. (1967) A rating scale of the mental state: for use in the chronic population of the psychiatric hospital. British Journal of Psychiatry, 113, 941–9.CrossRefGoogle ScholarPubMed
Johnstone, E. C., Crow, T. J. & Mashiter, K. (1977) Anterior pituitary hormone secretion in chronic schizophrenia—an approach to neurohumoral mechanisms. Psychological Medicine, 7, 223–8.CrossRefGoogle ScholarPubMed
Judd, S. J., Lazarus, L. & Smythe, G. (1976) Prolactin secretion by metoclopramide in man. Journal of Clinical Endocrinology and Metabolism, 43, 313–7.CrossRefGoogle ScholarPubMed
Kelly, J. G. & McDevitt, D. G. (1978) Plasma protein binding of propranolol and isoprenaline in hyperthyroidism and hypothyroidism. British Journal of Clinical Pharmacology, 6, 123–7.CrossRefGoogle Scholar
Martindale, W. (1977) The Extra Pharmacopoeia 27th edition (eds. A. Wade and J. E. F. Reynolds). London, The Pharmeutical Press, p. 1314.Google Scholar
Meltzer, H. Y., Sachar, E. J. & Frantz, A. G. (1974) Serum prolactin levels in unmedicated schizophrenic patients. Archives of General Psychiatry, 31, 564–9.CrossRefGoogle ScholarPubMed
Myers, M. G., Lewis, P. J., Reid, J. L. & Dollery, C T. (1975) Brain concentration of propranolol in relation to hypotensive effect in the rabbit with observations on brain propranolol levels in man. Journal of Pharmacology and Experimental Therapeutics, 192, 327–35.Google ScholarPubMed
Overall, J. E. & Gorhah, D. R. (1962) The brief psychiatric rating scale. Psychological Reports, 10, 799–812.CrossRefGoogle Scholar
Post, R. M. & Goodwin, F. K. (1975) Time-dependent effects of phenothiazines on dopamine turnover in psychiatric patients. Science, 190, 488–9.CrossRefGoogle ScholarPubMed
Praag, H. M. van & Korf, J. (1975) Biochemical research into psychosis. Acta Psychiatrica Scandinavica, 51, 268–84.Google ScholarPubMed
Shand, D. G., Nuckolls, E. M. & Oates, J. A. (1970) Plasma propranolol levels in adults with observations in four children. Clinical Pharmacology and Therapeutics, 11, 112–20.CrossRefGoogle ScholarPubMed
Sheppard, G. P. (1979) High-dose propranolol in schizophrenia. British Journal of Psychiatry, 134, 470–6.CrossRefGoogle ScholarPubMed
Taylor, E. A., Carroll, D. & Jefferson, D. (1979) CSF plasma ratios of propranolol and pindolol in man. Proceedings of the British Pharmacological Society, p. 27.CrossRefGoogle Scholar
Taylor, E. A., Carroll, D. & Turner, P. (1978) CSF plasma ratios of propranolol in man. British Journal of Clinical Pharmacology, 6, 447 p.CrossRefGoogle ScholarPubMed
Wiles, D. H., Kolakowska, T., McNeilly, A. S., Mandelbrote, B. M. & Gelder, M. G. (1976) Clinical significance of plasma chlorpromazine levels I. Plasma levels of the drug, some of its metabolites and prolactin during acute treatment. Psychological Medicine, 6, 407–15.CrossRefGoogle ScholarPubMed
Wilson, J. D., King, D. J. & Sheridan, B. (1979) Plasma prolactin levels before and during propranolol treatment in chronic schizophrenia. British Journal of Clinical Pharmacology, 7, 313–4.CrossRefGoogle ScholarPubMed
Wing, J. K. (1961) A simple and reliable subclassification of chronic schizophrenia. Journal of Mental Science, 107, 862–75.CrossRefGoogle ScholarPubMed
Wing, J. K., Cooper, J. E. & Sartorius, N. (1974) Measurement and classification of psychiatric symptoms. Cambridge University Press. Google Scholar
Wode-Helgodt, B., Fyrö, B., Gullberg, B. & Sedvall, G. (1977) Effect of chlorpromazine treatment on monoamine metabolite levels in cerebrospinal fluid of psychotic patients. Acta Psychiatrica Scandinavica, 56, 129–42.Google ScholarPubMed
Yorkston, N. J., Gruzelier, J. H., Zaki, S. A., Hollander, D., Pitcher, D. R. & Sergeant, H. G. S. (1977a) Propranolol in chronic schizophrenia. Lancet, ii, 1082–3.Google Scholar
Yorkston, N. J., Gruzelier, J. H., Zaki, S. A., Hollander, D., Pitcher, D. R. & Sergeant, H. G. S. (1977b) Propranolol as an adjunct to the treatment of schizophrenia. Lancet, ii, 575–6.Google Scholar
Yorkston, N. J., Zaki, S. A., Malik, M. K. U., Morrison, R. C. & Havard, C. W. H. (1974) Propranolol in the control of schizophrenic symptoms. British Medical Journal, iv, 633–5.Google Scholar
Yorkston, N. J., Zaki, S. A., Themen, J. F. A. & Havard, C. W. H. (1976a) Safeguards in the treatment of schizophrenia with propranolol. Postgraduate Medical Journal, 52 (Supplement 4), 175–80.Google ScholarPubMed
Yorkston, N. J., Zaki, S. A., Themen, J. F. A. & Havard, C. W. H. (1976b) Propranolol to control schizophrenic symptoms: 55 patients. Advances in Clinical Pharmacology, 12, 91–104.Google Scholar
Zerssen, D. van (1976) Beta-adrenergic blocking agents in the treatment of psychoses. A report on 17 cases. Advances in Clinical Pharmacology, 12, 105–14.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.